Table 2 –
Characteristics of concordant versus discordant risk groups according to standard risk criteria versus omega scorea
| Characteristic | Standard: low/FIR Omega score: low |
Standard: low/FIR Omega score: high |
p value | Standard: UIR/high Omega score: low |
Standard: UIR/high Omega score: high |
p value |
|---|---|---|---|---|---|---|
| Sample size | 710 | 286 | 175 | 593 | ||
| Age (yr), mean (SD) | 71.0 (4.8) | 64.9 (7.4) | <0.001 | 73.0 (4.3) | 69.7 (6.3) | <0.001 |
| Karnofsky performance status | ||||||
| 70–80 | 66 (9.3) | 12 (4.2) | 0.01 | 31 (17.7) | 29 (4.9) | <0.001 |
| 80–90 | 644 (90.7) | 274 (95.8) | 144 (82.3) | 563 (95.1) | ||
| Comorbidity | ||||||
| Any | 627 (88.3) | 102 (35.6) | <0.001 | 176 (100.0) | 393 (66.3) | <0.001 |
| Cardiovascular | 306 (43.1) | 30 (10.5) | <0.001 | 110 (62.9) | 120 (20.2) | <0.001 |
| Diabetes | 149 (21.0) | 18 (6.3) | <0.001 | 55 (31.4) | 80 (13.5) | <0.001 |
| T category | ||||||
| T1–T2a | 678 (95.5) | 261 (91.3) | 134 (76.6) | 349 (58.9) | <0.001 | |
| T2b | 32 (4.5) | 25 (8.7) | 0.014 | 41 (23.4) | 244 (41.1) | |
| Gleason score | ||||||
| ≤6 | 661 (93.1) | 255 (89.2) | 0.052 | 66 (37.7) | 109 (18.4) | <0.001 |
| 3 + 4 | 49 (6.9) | 31 (10.8) | 59 (33.7) | 169 (28.5) | ||
| 4 + 3 | 0 | 0 (0) | – | 46 (26.3) | 134 (22.6) | |
| ≥8 | 0 | 0 (0) | – | 4 (2.3) | 181 (30.5) | |
| PSA (ng/ml), mean (SD) | 6.9 (3.5) | 8.7 (4.1) | <0.001 | 8.7 (3.9) | 10.8 (4.4) | <0.001 |
| ≥50% positive cores | 0 (0) | 0 (0) | – | 107 (76.4) b | 184 (57.9) b | <0.001 |
FIR = favourable intermediate risk; PSA = prostate-specific antigen; SD = standard deviation; UIR = unfavourable intermediate risk.
a
Data are presented as n (%) unless otherwise indicated.
b
Percentage is of nonmissing. Two-sided p values are from t test (continuous variables), Pearson's chi-square test with Yates' continuity correction (categorical variables), or Fisher’s exact test (for categorical variables with fewer than five counts in any category).